US2014336362A1PendingUtilityA1
Avian Derived Antibodies
Est. expiryMay 27, 2029(~2.9 yrs left)· nominal 20-yr term from priority
Inventors:Alex J. Harvey
A01K 2267/01C07K 2317/732A01K 67/0275A01K 2267/02Y10S530/867C07K 2317/24C07K 16/2887A01K 2227/30C07K 2317/23A01K 2217/052Y10S424/80Y10S424/801C07K 2317/734C07K 2317/41C12N 15/8509A61P 37/04
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produces in a transgenic avian. The antibody molecules have a heavy chain and a light chain and exhibit an increased level of antibody-dependent cell-mediated cytotoxicity (ADCC) as compared to that of anti-CD20 antibody molecules produced by CHO cells.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produced in a transgenic avian, wherein the antibody molecules comprise a heavy chain and a light chain whose amino acid sequences set forth from position 23 to position 235 of SEQ ID NO:1 and from position 20 to position 470 of SEQ ID NO: 2, respectively, wherein the isolated mixture of cytotoxic anti-CD20 antibody molecules exhibit an increased level of antibody-dependent cell-mediated cytotoxicity (ADCC) as compared to that of anti-CD20 antibody molecules produced in CHO cells and having the same amino acid sequence.
2 . The composition of claim 1 , wherein the isolated mixture of the anti-CD20 antibody molecules are produced in tubular gland cells of the transgenic avian.
3 . The composition of claim 2 , wherein the transgenic avian is selected from the group consisting of a chicken, a quail and a turkey.
4 . The composition of claim 3 , wherein the transgenic avian is a chicken.
5 . The composition of claim 4 , wherein the cytotoxic anti-CD20 antibody molecules are isolated from egg white of the transgenic chicken.
6 . The composition of claim 1 , wherein about 95% or more of the N-linked oligosaccharide structures present on the antibody molecules do not contain fucose.Join the waitlist — get patent alerts
Track US2014336362A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.